Updated on 2025/06/06

写真a

 
HUANG PENG
 
Organization
Scheduled update Assistant Professor
Position
Assistant Professor
External link

Degree

  • 医学博士 ( 2009.3   岡山大学 )

  • Medical Doctor ( 2009.3   Okayama University )

Research Interests

  • Gene Therapy; Inmuotherapy; Regenretive Medicine: Rhabdomyosarcoma; Exosome;Immune escape;Molecular imaging

Research Areas

  • Life Science / Tumor diagnostics and therapeutics

  • Life Science / Tumor biology

  • Life Science / Urology

  • Life Science / Immunology

  • Life Science / Radiological sciences

Education

  • Okayama University   大学院医歯薬学総合研究科  

    2005.4 - 2009.3

      More details

    Country: Japan

    researchmap

 

Papers

  • The Early Response After Radiation Therapy on Three-Dimensional Oral Cancer Model Using Patient-Derived Cancer-Associated Fibroblasts

    Izumi Yamamoto, Kazuyo Igawa, Natsuko Kondo, Yoshinori Sakurai, Atsushi Fujimura, Kiyofumi Takabatake, Peng Huang, Hiroyuki Michiue, Soichiro Ibaragi, Kenji Izumi

    International Journal of Translational Medicine   5 ( 1 )   12 - 12   2025.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Background/Objectives: Cancer-associated fibroblasts (CAFs), which are an important component of the tumor microenvironment, have been reported to have an adverse effect on conventional radiotherapy. This study aims to elucidate the effects of CAFs in boron neutron capture therapy (BNCT) using a three-dimensional (3D) oral cancer model. Methods: Three-dimensional cancer models were fabricated using patient-derived CAFs or patient-derived normal oral fibroblasts (NOFs) and a human oral squamous cell carcinoma cell line. Each 3D cancer model was performed with either a conventional X-ray treatment or BNCT and additionally analyzed histomorphologically. Results: The 3D oral cancer-CAFs model demonstrated a greater depth of cancer cell invasion than the 3D oral cancer-NOFs model. Radiation therapy for the 3D oral cancer models indicated a trend for decreasing cancer cell invasion and cell number with dose dependence in both X-ray and BNCT. In comparison with X-rays, BNCT showed a consistent increase in the number of NOFs and a significant reduction in the number of CAFs. Conclusions: BNCT for the 3D oral cancer model was shown to be effective against cancer cells and CAFs but not against NOFs, indicating its usefulness as a minimally invasive treatment for advanced cancer. Furthermore, it is indicated that the 3D oral cancer-CAFs model is a valuable tool to evaluate cancer treatment and research, particularly in high-grade malignant tumors with invasion.

    DOI: 10.3390/ijtm5010012

    researchmap

  • The Necroptotic Process-Related Signature Predicts Immune Infiltration and Drug Sensitivity in Kidney Renal Papillary Cell Carcinoma. Reviewed International journal

    Wenfeng Lin, Ruizhi Xue, Hideo Ueki, Peng Huang

    Current cancer drug targets   2024.4

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: It remains controversial whether the current subtypes of kidney renal papillary cell carcinoma (KIRP) can be used to predict the prognosis independently. OBJECTIVE: This observational study aimed to identify a risk signature based on necroptotic pro-cess-related genes (NPRGs) in KIRP. METHODS: In the training cohort, LASSO regression was applied to construct the risk signature from 158 NPRGs, followed by the analysis of Overall Survival (OS) using the Kaplan-Meier method. The signature accuracy was evaluated by the Receiver Operating Characteristic (ROC) curve, which was further validated by the test cohort. Wilcoxon test was used to compare the expressions of immune-related genes, neoantigen genes, and immune infiltration between differ-ent risk groups, while the correlation test was performed between NPRGs expressions and drug sensitivity. Gene set enrichment analysis was used to investigate the NPRGs' signature's biologi-cal functions. RESULTS: We finally screened out 4-NPRGs (BIRC3, CAMK2B, PYGM, and TRADD) for con-structing the risk signature with the area under the ROC curve (AUC) reaching about 0.8. The risk score could be used as an independent OS predictor. Consistent with the enriched signaling, the NPRGs signature was found to be closely associated with neoantigen, immune cell infiltration, and immune-related functions. Based on NPRGs expressions, we also predicted multiple drugs potentially sensitive or resistant to treatment. CONCLUSION: The novel 4-NPRGs risk signature can predict the prognosis, immune infiltration, and therapeutic sensitivity of KIRP.

    DOI: 10.2174/0115680096286503240321040556

    PubMed

    researchmap

  • The current status and novel advances of boron neutron capture therapy clinical trials. Reviewed International journal

    Tianyun Zhou, Kazuyo Igawa, Tomonari Kasai, Takuya Sadahira, Wei Wang, Tomofumi Watanabe, Kensuke Bekku, Satoshi Katayama, Takehiro Iwata, Tadashi Hanafusa, Abai Xu, Motoo Araki, Hiroyuki Michiue, Peng Huang

    American journal of cancer research   14 ( 2 )   429 - 447   2024.2

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Boron neutron capture therapy (BNCT) is a treatment method that focuses on improving the cure rate of patients with cancer who are difficult to treat using traditional clinical methods. By utilizing the high neutron absorption cross-section of boron, material rich in boron inside tumor cells can absorb neutrons and release high-energy ions, thereby destroying tumor cells. Owing to the short range of alpha particles, this method can precisely target tumor cells while minimizing the inflicted damage to the surrounding normal tissues, making it a potentially advantageous method for treating tumors. Globally, institutions have progressed in registered clinical trials of BNCT for multiple body parts. This review summarized the current achievements in registered clinical trials, Investigator-initiated clinical trials, aimed to integrate the latest clinical research literature on BNCT and to shed light on future study directions.

    PubMed

    researchmap

  • Exploration of the protein-dependent mechanism of Lactobacillus crispatus GAI98322 to prevent recurrent cystitis. International journal

    Tomofumi Watanabe, Takuya Sadahira, Hidetada Hirakawa, Peng Huang, Tianyun Zhou, Takehiro Iwata, Takanori Sekito, Ayano Ishii, Masami Watanabe, Motoo Araki

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   29 ( 10 )   1001 - 1004   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: To elucidate the mechanism of Lactobacillus crispatus (L. crispatus) suppositories to prevent patients from recurrent cystitis (RC), independent from viable-Lactobacilli-bacteria- and acid-dependent ones such as hydrogen peroxide and lactate. METHODS: We used the GAI98322 strain of L. crispatus in all experiments and pH-matched. cell-free culture supernatant of L. crispatus (CFCS) was collected. The growth inhibitory activity and the biofilm formation inhibitory activity of the CFCS against uropathogenic Escherichia coli (UPEC), Extended Spectrum beta (β) Lactamase producing (ESBL+) UPEC, and Pseudomonas aeruginosa (P. aeruginosa) was assessed by agar-disk diffusion tests and crystal violet assay. Also, CFCS was subjected to mass spectrometry to specify ingredients. RESULTS: The CFCS suppressed the proliferation of E. coli, ESBL + E. coli, and P. aeruginosa. Also, the CFCS at a concentration of 40% significantly impeded the biofilm formation of these three bacteria. The aggregation-promoting factor and Lysin was detected from CFCS. CONCLUSIONS: The cell-free supernatant from the GAI98322 strain of L. crispatus inhibits the growth/biofilm formation of broad pathogens by aggregation promoting factor and lysin, which may prevent hosts from RC regardless of the antimicrobial resistance of the pathogens and even under pH modulation.

    DOI: 10.1016/j.jiac.2023.06.013

    PubMed

    researchmap

  • Dkk3/REIC Deficiency Impairs Spermiation, Sperm Fibrous Sheath Integrity and the Sperm Motility of Mice. Reviewed International journal

    Ruizhi Xue, Wenfeng Lin, Hirofumi Fujita, Jingkai Sun, Rie Kinoshita, Kazuhiko Ochiai, Junichiro Futami, Masami Watanabe, Hideyo Ohuchi, Masakiyo Sakaguchi, Zhengyan Tang, Peng Huang, Yasutomo Nasu, Hiromi Kumon

    Genes   13 ( 2 )   2022.1

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    The role of Dickkopf-3 (Dkk3)/REIC (The Reduced Expression in Immortalized Cells), a Wnt-signaling inhibitor, in male reproductive physiology remains unknown thus far. To explore the functional details of Dkk3/REIC in the male reproductive process, we studied the Dkk3/REIC knock-out (KO) mouse model. By examining testicular sections and investigating the sperm characteristics (count, vitality and motility) and ultrastructure, we compared the reproductive features between Dkk3/REIC-KO and wild-type (WT) male mice. To further explore the underlying molecular mechanism, we performed RNA sequencing (RNA-seq) analysis of testicular tissues. Our results showed that spermiation failure existed in seminiferous tubules of Dkk3/REIC-KO mice, and sperm from Dkk3/REIC-KO mice exhibited inferior motility (44.09 ± 8.12% vs. 23.26 ± 10.02%, p < 0.01). The Ultrastructure examination revealed defects in the sperm fibrous sheath of KO mice. Although the average count of Dkk3/REIC-KO epididymal sperm was less than that of the wild-types (9.30 ± 0.69 vs. 8.27 ± 0.87, ×106), neither the gap (p > 0.05) nor the difference in the sperm vitality rate (72.83 ± 1.55% vs. 72.50 ± 0.71%, p > 0.05) were statistically significant. The RNA-seq and GO (Gene Oncology) enrichment results indicated that the differential genes were significantly enriched in the GO terms of cytoskeleton function, cAMP signaling and calcium ion binding. Collectively, our research demonstrates that Dkk3/REIC is involved in the process of spermiation, fibrous sheath integrity maintenance and sperm motility of mice.

    DOI: 10.3390/genes13020285

    PubMed

    researchmap

▼display all

MISC

  • Tracking and Imaging of Tumor Progression and Immune Function in a Preclinical Mouse Model

    Peng Huang, Naijin Xu, Eiji Matsuura, Masami Watanbe, Hiromi Kumon, Yasutomo Nasu, Chunxiao Liu

    MOLECULAR THERAPY   25 ( 5 )   98 - 98   2017.5

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • REAL-TIME MONITORING OF TUMOR PROGRESSION AND DRUG RESPONSES IN A PRECLINICAL MOUSE MODEL OF PROSTATE CANCER

    Peng Huang, Peng Xu, Xiezhao Li, Naijin Xu, Abai Xu, Masami Watanabe, Hiromi Kumon, Chunxiao Liu, Yasutomo Nasu

    JOURNAL OF UROLOGY   197 ( 4 )   E598 - E598   2017.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • IMMUNE CHECKPOINT INHIBITOR COMBINED WITH THE GROWTH INHIBITOR LYCORINE SYNERGISTICALLY FUNCTION TO MEDIATE ANTI-TUMOR EFFECTS IN A MOUSE MODEL OF RENAL CELL CARCINOMA

    Xiezhao Li, Naijin Xu, Aibai Xu, Masami Watanabe, Peng Huang, Yasutomo Nasu, Chunxiao Liu

    JOURNAL OF UROLOGY   197 ( 4 )   E963 - E963   2017.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • INDUCTION OF PROSTATE CANCER STEM CELL PROPERTIES IN MOUSE INDUCED PLURIPOTENT STEM CELLS VIA DEFINED CARCINOMA NICHE AND TRACKING DRUG RESPONSE IN PRECLINICAL RESEARCH

    Naijin Xu, Xiezhao Li, Aibai Xu, Masami Watanabe, Peng Huang, Yasutomo Nasu, Chunxiao Liu

    JOURNAL OF UROLOGY   197 ( 4 )   E540 - E540   2017.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging

    H. Kaku, H. Ueki, Y. Ariyoshi, S. Li, P. Huang, Y. Nasu, H. Kumon, M. Watanabe

    HUMAN GENE THERAPY   24 ( 12 )   A154 - A154   2013.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

▼display all

Industrial property rights

  • トリアゾール誘導体の用途

    黄 鵬, 渡部昌実, 林 文鋒

     More details

    Applicant:国立大学法人岡山大学

    Application no:特願2021-053244  Date applied:2021.3.26

    researchmap

  • Combinational Use of Nitroxoline and Its Analogues with Chemotherapies and Immunotherapies in the Treatment of Cancer

    Ke PAN, Peng HUANG, Qiang LI

     More details

    Applicant:Asieris Pharmaceutical Technologies Co., Ltd.

    Application no:特願16089800  Date applied:2017.3.31

    Announcement no:特開20190275025  Date announced:2019.9.12

    Patent/Registration no:特許WO/2017/173278  Date registered:2017.3.31  Date issued:2017.10.5

    researchmap

  • PET imaging technology to visualize the therapeutic effect and GVHD in cell therapy by transplantation of transgenic lymphocytes

     More details

    Applicant:Okayama University

    Application no:特願2016-066068  Date applied:2016.3.29

    Announcement no:特開2017-178818  Date announced:2017.10.5

    Patent/Registration no:特許6707256  Date registered:2020.5.22 

    researchmap

Awards

  • American Urological Association 2018(AUA2018) Best Poster Winner

    2018.5   American Urological Association  

     More details

Research Projects

  • Drug discovery of next-generation circular mRNA vaccine platform targeting tumor immune escape mechanism

    Grant number:22KK0288  2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))

    黄 鵬

      More details

    Grant amount:\15210000 ( Direct expense: \11700000 、 Indirect expense:\3510000 )

    researchmap

  • 骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索

    Grant number:21K09371  2021.04 - 2024.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    黄 鵬, 渡部 昌実, 荒木 元朗, 植木 英雄

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    癌の研究開発において、癌免疫逃避機構に関する最近の注目すべき研究として、骨髄由来免疫抑制細胞(MDSC: myeloid-derived suppresser cell)が、癌に対する免疫監視機構や抗腫瘍免疫を負に制御して癌の悪性進展の中心的役割を担っていることが明らかにされつつある。本申請研究では、骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索を目指している。本年度は、
    ①前立腺がん担癌マウスより末梢血を採収後FACS AriaでMDSSC細胞を分離し、MDSC細胞の表面マーカーの確認を行った。分離したMDSC細胞に対するREIC/Dkk-3タンバク質の抑制効果の観点から解析した。さらに、Ad-REICの抗癌作用に基づく免疫逃避応答に関する機序を解明し、その有効性を検証した。
    ②分離したMDSC細胞にREIC/Dkk-3タンパク質を作用させ、1分、30分、1時間、6時間、24時間後細胞内タンパク質を抽出し、または特異的siRNAによりノックダウンさせ、遺伝子-タンパク質発現変動をマイクロアレイやタンパク質抗体アレイ等により解析した。また、Western blot法により関連したパスウェイ内の各種タンパク質およびそのリン酸化の動態を実験した。
    ③細胞核内の標的遺伝子群(転写されるタンパク質群)の同定を行い、REIC/Dkk-3とMDSC細胞膜上での結合分子・受容体の同定解析を行った。

    researchmap

  • 治療抵抗性前立腺癌における癌化-ステロイドシグナルaxisの機構解明

    Grant number:21K09423  2021.04 - 2024.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    小林 泰之, 那須 保友, 荒木 元朗, 定平 卓也, 黄 鵬

      More details

    Grant amount:\3900000 ( Direct expense: \3000000 、 Indirect expense:\900000 )

    新規CYP17A1阻害薬の登場により、ホルモン治療抵抗性前立腺癌の治療に大きな変化がもたらされ、副腎由来のアンドロゲンの重要性が再認識された。しかし、一定の成果が得られたものの治療の限界が存在することが明らかとなった。その治療抵抗性の機序はステロイドレセプターを介するものが主体であり、さらなる知見の集積が求められている。我々は近年、癌抑制遺伝子REIC/Dkk-3の発現そのものが癌化を根源的に抑制する機能を有し、特に発癌の過程においてREIC/Dkk-3の発現低下が極めて重要な因子になることに着目してきた。REIC/Dkk-3の発現そのものが生体内において直接的にRasシグナリングを介した発癌を抑制している。一方で、REIC/Dkk-3に結合するタンパク質としてSGTAとTCTX-1を発見し、それらの相互作用が未熟なステロイドレセプター複合体の成熟を制御している可能性を見出している。これらの知見を踏まえ、本申請研究では、治療抵抗性前立腺癌における癌化-ステロイドシグナルaxisの機構の実態を明らかにし、その分子メカニズムに焦点を当てて研究を行い、革新的癌創薬への展開を目指した。令和3年度では、GR(グルココルチコイドレセプター)に注目した研究をした。SGTAとREIC/Dkk-3が相互作用し、ステロイドレセプターの核内輸送を制御していることを明らかにした。本年度では特にGRに注目した研究解析を行なっており、REIC/Dkk-3がGRの輸送に重要な役割を担っていることを明らかにした。引き続き、去勢抵抗性前立腺癌の治療変革を目指した解析をREIC/Dkk-3を軸に検証していく予定である。

    researchmap

  • 細胞骨格ダイナミクスに基づく分子輸送制御システムの解明と革新的癌創薬への新展開

    Grant number:19H01064  2019.04 - 2024.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A)  Grant-in-Aid for Scientific Research (A)

    渡部 昌実, 定平 卓也, 黄 鵬, 竹居 孝二, 竹田 哲也, 落合 和彦, 野口 洋文, 山田 浩司, 那須 保友

      More details

    Grant amount:\40300000 ( Direct expense: \31000000 、 Indirect expense:\9300000 )

    各種癌細胞を入手すると同時に、より普遍性の高い研究を遂行する為、独自のマウス間葉系幹細胞を樹立した。各種癌細胞において、細胞骨格因子が関わる細胞内分子輸送システムに重要と考えられるタンパク質群の発現を網羅的に解析した。特に、REIC/Dkk-3、SGTA、Tctex-1、Dyneinモーター、Dynaminおよびその他の細胞骨格(制御)因子に着目して、それら関連分子を含め発現を解析した。一部のタンパク質においてはその発現を認めず、免疫組織学的な解析を行うべく準備を進めた。これまでの男性ホルモンレセプターの核内移行に基づく実験系に加え、糖質コルチコイドレセプターの核内移行に基づく表現型解析系を立ち上げた。また癌創薬の観点から複数のDynamin阻害薬に関する検討を行い、in vivo投与での作用機序解明に係る動物実験での解析系の立ち上げを行った。

    researchmap

  • Basic research on next-generation gene therapy using restricted-replication adenovirus

    Grant number:18K09194  2018.04 - 2021.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Kobayashi Yasuyuki

      More details

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    Our studies so far have confirmed the induction of cancer cell-selective apoptosis based on the forced expression of the cancer-therapeutic gene REIC on various cancer cells and the antitumor effect based on the action. In this study, REIC-expressing restricted-replication adenovirus vector (Oncolytic Ad-REIC) is expected to have a stronger antitumor effect than the conventional REIC-expressing non-replication adenovirus vector (Ad-REIC). We carried out a basic research for the clinical application of Oncolytic Ad-REIC. Assuming that the Oncolytic Ad-REIC is directly administered to the lesions of various cancer types in clinical practice, a study aimed at maximizing and optimizing the therapeutic effect of local cancer therapy was conducted.

    researchmap

▼display all